Study Finds RSV Vaccines Protect Older Adults with 75 Percent Effectiveness
A comprehensive new study published in JAMA Network Open revealed that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged 60 and older, with approximately 75 percent effectiveness against RSV-associated respiratory illness. In the study, researchers analyzed data from more than 787,000 older adults tested for RSV between October 2023 and April 2024, […]
Blood Test Can Predict How Long Vaccine Immunity Will Last
A study led by researchers at Stanford Medicine has shown that variation in vaccine durability can, in part, be attributed to a type of blood cell called megakaryocytes, typically implicated in blood clotting.
Coupling HA Molecules from Various Flu Strains Could Make Vaccines More Effective
Results from a recent study suggest coupling HA molecules from various flu strains could make flu vaccines more effective.
FDA Approves Chikungunya Vaccine
The U.S. Food and Drug Administration (FDA) has approved VIMKUNYA (chikungunya vaccine, recombinant) for injection, the first virus-like particle (VLP) single-dose chikungunya vaccine in the U.S. for persons 12 years of age and older.
Update on Rabies
Though mostly eradicated in the U.S., treatment for rabies must begin immediately with hyperimmune globulin and vaccines.
GSK’s Penmenvy Meningococcal Vaccine Approved by FDA
GSK’s Penmenvy (meningococcal groups A, B, C, W and Y vaccine) has been approved by the U.S. Food and Drug Administration for use in individuals aged 10 through 25 years.
RSV Vaccine Prompts Robust Response in Older Recipients
Findings of a Phase III randomized controlled trial showed Pfizer’s RSV Prefusion F (RSVpreF) vaccine triggered strong immune responses among people aged 60 years and older during its first two seasons.
Grant Awarded to Accelerate Pandemic Influenza mRNA Vaccine Development
The U.S. Department of Health andHuman Services will provide approximately $590 million to Moderna to accelerate the development of mRNAbased pandemic influenza vaccines and enhance mRNA platform capabilities
New Personalized Vaccine May Treat Pancreatic Cancer
A new study published in the journal Nature found that a personalized vaccine, named autogene cevumeran, is showing promising results for treating pancreatic cancer, one of the deadliest malignancies.
Vaccine Shows Promise In Stopping Plaque Buildup in Arteries
Chinese researchers have developed a “cocktail” nanovaccine to prevent plaque from building up in the arteries, an underlying factor in heart disease, which is the leading cause of death worldwide.
